1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Australia >
  5. Certa Acquires OccuRx

M&A Deal Summary

Certa Acquires OccuRx

On December 19, 2024, Certa acquired life science company OccuRx

Acquisition Highlights
  • This is Certa’s 1st transaction in the Life Science sector.
  • This is Certa’s 1st transaction in Australia.

M&A Deal Summary
Date 2024-12-19
Target OccuRx
Sector Life Science
Buyer(s) Certa
Deal Type Add-on Acquisition

Target

OccuRx

Melbourne, Australia
OccuRx is a biotechnology company with highly complementary assets, resources, and expertise, and a shared focus on targeting GPR68, a master switch of fibrosis. OccuRx is based in Melbourne, Australia.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Certa

Melbourne, Australia
Category Company
Sector Life Science
DESCRIPTION

Certa Therapeutics is a clinical-stage biotechnology company pioneering innovative precision therapies for the treatment of fibrotic diseases an area of significant unmet need, responsible for an estimated 45% of all deaths globally and representing a $15 billion market. Its platform targets a critical 'master switch' of fibrosis, GPR68 (a defined G protein-coupled receptor (GPCR)), with a pipeline of inhibitors for various fibrotic indications. Certa Therapeutics is based in Melbourne, Australia.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Australia M&A 1 of 1
Year: 2024 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal